The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m(2)) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy

PURPOSE: When used in the second-line setting, single-agent chemotherapy has produced response rates of more than 10% or median survival times greater than 4 months. We studied the safety and efficacy of using second-line single docetaxel (75 mg/m(2)) for advanced NSCLC patients who were previously...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Shim, Byoung Yong, Kim, Chi Hong, Song, So Hyang, Ahn, Meyung Im, Hong, Eun Jung, Kim, Sung Whan, Kim, Suzy, Jo, Min Seop, Cho, Deog Gon, Cho, Kyu Do, Yoo, Jinyoung, Kim, Hoon-Kyo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Korean Cancer Association 2005
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2785941/
https://ncbi.nlm.nih.gov/pubmed/19956369
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2005.37.6.339
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak